Literature DB >> 14684437

Glutamate receptors and transporters in the hippocampus in schizophrenia.

Paul J Harrison1, Amanda J Law, Sharon L Eastwood.   

Abstract

Postmortem studies, using various methods and directed at several molecular targets, have provided increasing evidence that glutamatergic neurotransmission is affected in schizophrenia. The bulk of the data are in the hippocampus, wherein there is reduced expression of one or more subunits for all three ionotropic receptors (NMDA, AMPA, and kainate). Presynaptic glutamatergic markers, notably the vesicular glutamate transporter VGLUT1, may also be decreased in schizophrenia, especially in older subjects. CA1 appears less affected than other subfields, and the decrements may be greater in the left than in the right hippocampus. The recently described susceptibility genes for schizophrenia all act upon glutamatergic synaptic transmission, which may, therefore, be part of the core pathophysiology of the disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684437     DOI: 10.1196/annals.1300.006

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  49 in total

Review 1.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

3.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

Review 4.  Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations.

Authors:  Alison R Preston; Daphna Shohamy; Carol A Tamminga; Anthony D Wagner
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

5.  Relating the effects of prenatal stress in rodents to the pathogenesis of schizophrenia.

Authors:  Holly Moore; Ezra Susser
Journal:  Biol Psychiatry       Date:  2011-11-15       Impact factor: 13.382

6.  Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Authors:  Oliver Grimm; Natalia Gass; Wolfgang Weber-Fahr; Alexander Sartorius; Esther Schenker; Michael Spedding; Celine Risterucci; Janina Isabel Schweiger; Andreas Böhringer; Zhenxiang Zang; Heike Tost; Adam James Schwarz; Andreas Meyer-Lindenberg
Journal:  Psychopharmacology (Berl)       Date:  2015-07-18       Impact factor: 4.530

7.  Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression.

Authors:  S Weis; I C Llenos; J R Dulay; N Verma; S Sabunciyan; R H Yolken
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

8.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

9.  An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia.

Authors:  Junko Sato; Dai Shimazu; Naoki Yamamoto; Toru Nishikawa
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

10.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.